The Pharmacological Toxicology Of The Reynolds

①Effective angina pectoris: In vitro studies showed that dogs in the duodenum were significantly reduced by coronary artery ligation in the St-T segment caused by electrical cardiac pacing (200 times/sub) in Ranolazine or Atenolol after anesthesia. This effect of Ranolazine lasted 3 hours without altering any hemodynamic parameters, whereas the use of Atenolol was accompanied by an elevated or decreased heart rate and diastolic blood pressure. The rat stomach gives Ranolazine, weakening the ST segment raised by Adrenaline. These results suggest that Ranolazine can effectively resist angina pectoris and do not alter any kinetic parameters.

②Do not affect heart rate and blood pressure: 14 patients with chronic stable angina pectoris in a single-blind placebo-controlled trial, the patient took the placebo two weeks after oral Ranolazine 30mg (one Days three times), 2 weeks after consecutive oral 60mg (one days three times), for two weeks. The results showed that the heart rate and systolic blood pressure, the heart rate and systolic compression after the two doses were not changed markedly compared with the placebo control group.

③ The new mechanism: the existing medication for angina pectoris is functioning by direct reduction of cardiac work (heart rate and/or blood pressure). Ranolazine is an inhibitor of pFOX (partial fatty acid oxidase) and reduces cardiac oxygen demand by altering the cardiac metabolism. Cardiac metabolism is the use of oxygen oxidation fatty acids or glucose production capacity. In normal physiological state, myocardial cells mainly use fatty acid oxidation capacity, and less use of glucose. PFOX inhibitors reduce fatty acid oxidation and increase glucose oxidation.